Medico Remedies Ltd Downgraded to Sell Amid Technical Weakness and Growth Concerns

Quality Assessment: Strong Operational Metrics Amidst Growth Concerns

Medico Remedies continues to demonstrate operational efficiency, highlighted by a robust Return on Capital Employed (ROCE) of 15.04%, which indicates effective utilisation of capital to generate profits. The company also maintains a strong debt servicing ability, with a low Debt to EBITDA ratio of 0.82 times, underscoring prudent financial management and limited leverage risk.

Financially, the firm has delivered positive results for five consecutive quarters, with the latest quarter (Q4 FY25-26) showing net sales of ₹56.81 crores, marking a 37.55% quarterly growth. Profitability metrics have also improved, with PBDIT reaching a peak of ₹7.15 crores and PBT (excluding other income) at ₹5.45 crores. These figures reflect operational resilience in a competitive pharmaceutical landscape.

However, despite these encouraging short-term results, the company’s long-term growth trajectory remains subdued. Net sales have grown at a compounded annual growth rate (CAGR) of just 14.28% over the past five years, which is modest relative to sector peers and insufficient to justify a higher rating. This slower growth rate weighs heavily on the overall quality grade, signalling caution for investors seeking sustained expansion.

Valuation: Fair but Discounted Relative to Peers

Medico Remedies’ valuation metrics present a mixed picture. The company’s ROCE of 15.8% and an Enterprise Value to Capital Employed (EV/CE) ratio of 4.6 suggest a fair valuation framework. Notably, the stock trades at a discount compared to the average historical valuations of its pharmaceutical peers, which could be attractive for value-oriented investors.

However, the stock’s price-to-earnings growth (PEG) ratio stands at 0.9, indicating that while profits have risen by 30% over the past year, the market has not fully priced in this earnings growth. Despite this, the stock’s year-to-date return of -18.3% and one-year return of -12.98% lag behind the Sensex’s respective returns of -13.36% and -10.52%, reflecting investor scepticism and valuation pressure.

Financial Trend: Positive Quarterly Performance Contrasted by Weak Long-Term Returns

Quarterly financial trends for Medico Remedies have been encouraging, with consistent growth in net sales and profitability over the last five quarters. The latest quarter’s 37.55% increase in net sales and record PBDIT and PBT figures underscore operational momentum.

Nevertheless, the company’s longer-term financial returns tell a different story. Over the past three years, the stock has declined by 50.56%, starkly underperforming the Sensex’s 17.90% gain. This divergence highlights challenges in sustaining growth and market confidence. The five-year return of 566.29% is impressive but appears to be an outlier compared to recent performance, suggesting a potential plateau or correction phase.

Technical Analysis: Downgrade Driven by Bearish Momentum

The primary catalyst for the downgrade to Sell is the deterioration in technical indicators, which have shifted from mildly bearish to outright bearish. Key technical signals include:

• MACD: Weekly readings remain mildly bullish, but monthly MACD has turned bearish, indicating weakening momentum over the longer term.
• RSI: Both weekly and monthly Relative Strength Index (RSI) show no clear signals, reflecting indecision and lack of strong directional momentum.
• Bollinger Bands: Both weekly and monthly bands are bearish, signalling increased volatility and downward pressure on price.
• Moving Averages: Daily moving averages are bearish, confirming short-term negative price trends.
• KST (Know Sure Thing): Weekly KST remains mildly bullish, but monthly KST is bearish, reinforcing mixed momentum signals.
• Dow Theory: Weekly trend is mildly bearish, while monthly trend shows no clear direction.
• On-Balance Volume (OBV): Weekly OBV is mildly bearish, suggesting selling pressure outweighs buying interest.

These technical factors have contributed significantly to the downgrade, as the stock’s price has declined 4.09% on the day of the rating change, closing at ₹41.31 from a previous close of ₹43.07. The 52-week high stands at ₹56.99, while the low is ₹31.00, indicating the stock is trading closer to its lower range amid bearish sentiment.

Shareholding and Market Capitalisation

Medico Remedies remains majority-owned by promoters, which often provides stability in governance and strategic direction. The company is classified as a micro-cap, which typically entails higher volatility and risk compared to larger-cap peers. This classification further justifies a cautious stance given the current technical and fundamental backdrop.

Conclusion: Downgrade Reflects Caution Amid Mixed Signals

Medico Remedies Ltd’s downgrade from Hold to Sell by MarketsMOJO on 11 June 2026 is a reflection of the complex interplay between solid short-term financial performance and weakening technical momentum. While the company exhibits strong management efficiency, low leverage, and positive quarterly growth, its long-term growth rate remains modest and the stock’s technical indicators have turned bearish.

Investors should weigh the company’s fair valuation and operational strengths against the risks posed by deteriorating price trends and subdued long-term returns. The downgrade signals a cautious approach, suggesting that despite pockets of strength, the stock currently lacks the momentum and growth profile to warrant a more favourable rating.

Market participants are advised to monitor upcoming quarterly results and technical developments closely, as any sustained improvement in growth or reversal in technical trends could prompt a reassessment of the stock’s outlook.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →